No Data
The pharmaceutical sector is performing strongly with the Hang Seng Healthcare Index up by 1.34%. Jingtailong Technology (02228) rose by 21.84%.
Golden Horse Financial News | Pharmaceutical stocks show strong performance, with the Hang Seng Healthcare Index up by 1.34%. Among them, Crystal Tai Technology quantumph-p (02228) rose by 21.84%, Yiming Angke (01541) rose by 9.94%, Zai Lab (09688) rose by 9.64%, Lifetech Sci (01302) rose by 5.22%, Lai Kai Medical (02105) rose by 5.52%, Tigermed (03347) rose by 5.36%. China Thai International stated that since October, there has been differentiation in the stock performance of the pharmaceutical industry, with components of the Hang Seng Healthcare Index showing a previous rise driven by easing policies.
Lai Kai Medicine - B [02105] is now trading at 9.59 Hong Kong dollars, with a 10.23% increase in the price.
As of 09:40, Kaixin Pharmaceutical - B [02105] reported HK$9.59, up HK$0.89 or 10.23% from the previous closing price of HK$8.70. The turnover was HK$9.1251 million, with today's highest price at HK$9.59 and lowest price at HK$8.87. Based on the previous day's closing price, the 10-day average price is HK$7.42, and the 50-day average price is HK$5.55. The current P/E ratio is -4.70 times, and the 14-day RSI is 69.04.
Abnormal statistics on the proportion of Smart Connect Hong Kong stocks | October 23rd
Abnormal statistics of the proportion of Shenzhen-Hong Kong Stock Connect transactions | October 22, 2024
HK stock market anomaly | Most pharmaceutical stocks are strong, with a number of bullish policies coming out successively this year, which is expected to promote the long-term increase in trading volume of innovative drugs in the country.
Many pharmaceutical stocks have performed well, as of the time of publication, Lai Kai zai lab-B (02105) rose by 12.27%, closing at 8.05 Hong Kong dollars; zai lab (09688) rose by 11.72%, closing at 22.4 Hong Kong dollars; and He Yu-B (02256) rose by 9.6%, closing at 3.88 Hong Kong dollars.
[Hong Kong Stock Connect] Lai Kai Medicine (02105) rose more than 10%. LAE102 Phase I clinical trial for the treatment of obesity started, studying subcutaneous injections.
Golden Finance News | Kai Medical (02105) morning stock price is strong, as of the time of submission, reported at 7.92 Hong Kong dollars, up by 10.46%, with a turnover of 26.1373 million Hong Kong dollars. In terms of news, the group has initiated the subcutaneous injection queue in its Phase I single dose escalation study (referred to as SAD study). This Phase I clinical trial is a randomized, double-blind, placebo-controlled study, aiming to evaluate the safety, tolerability, and pharmacokinetics of LAE102 injection solution through intravenous infusion and subcutaneous injection dosing methods. The Phase I clinical trial is progressing smoothly. As of September 30, 2024, more than half
Laekna Begins Phase I Clinical Trial for Obesity Treatment
No Data
No Data